Cerevel Therapeutics Holdings IncNASDAQ:CERE
- LAST PRICE33.3800
- TODAY'S CHANGE (%)0.8300 (2.5499%)
- Bid / Lots22.8000/ 1
- Ask / Lots33.8500/ 1
- Open / Previous Close32.9500 / 32.5500
- Day Range
- 52 Week Range
- Volume354,644
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CERE |
|---|---|---|
| 09:32 ET | 3293 | 32.96 |
| 09:36 ET | 1100 | 33.1375 |
| 09:38 ET | 1740 | 33.42 |
| 09:39 ET | 4428 | 33.15 |
| 09:41 ET | 800 | 32.95 |
| 09:43 ET | 300 | 32.945 |
| 09:48 ET | 300 | 32.93 |
| 09:52 ET | 400 | 32.79 |
| 09:54 ET | 200 | 32.82 |
| 09:56 ET | 500 | 32.95 |
| 09:57 ET | 1028 | 32.81 |
| 09:59 ET | 100 | 32.75 |
| 10:01 ET | 100 | 32.81 |
| 10:03 ET | 200 | 32.6721 |
| 10:06 ET | 1300 | 32.715 |
| 10:08 ET | 800 | 32.76 |
| 10:10 ET | 4103 | 32.72 |
| 10:12 ET | 300 | 32.82 |
| 10:14 ET | 2601 | 32.9 |
| 10:15 ET | 200 | 32.74 |
| 10:17 ET | 100 | 32.87 |
| 10:19 ET | 12770 | 33.05 |
| 10:21 ET | 3590 | 33.12 |
| 10:24 ET | 2686 | 33.08 |
| 10:26 ET | 600 | 33.13 |
| 10:28 ET | 300 | 33.21 |
| 10:32 ET | 900 | 33.18 |
| 10:35 ET | 200 | 33.17 |
| 10:37 ET | 300 | 33.16 |
| 10:39 ET | 1300 | 33.22 |
| 10:42 ET | 1400 | 33.26 |
| 10:44 ET | 100 | 33.25 |
| 10:46 ET | 100 | 33.23 |
| 10:48 ET | 300 | 33.14 |
| 10:50 ET | 100 | 33.11 |
| 10:51 ET | 200 | 33.01 |
| 10:53 ET | 200 | 32.985 |
| 10:55 ET | 100 | 32.945 |
| 10:57 ET | 410 | 32.91 |
| 11:00 ET | 693 | 32.98 |
| 11:02 ET | 200 | 33.06 |
| 11:04 ET | 100 | 33.09 |
| 11:06 ET | 100 | 33.04 |
| 11:09 ET | 600 | 33.05 |
| 11:11 ET | 300 | 33.09 |
| 11:13 ET | 1102 | 33.03 |
| 11:15 ET | 1800 | 33.045 |
| 11:18 ET | 370 | 33.1373 |
| 11:20 ET | 300 | 33.065 |
| 11:26 ET | 200 | 33.0075 |
| 11:27 ET | 300 | 33.03 |
| 11:31 ET | 200 | 32.97 |
| 11:38 ET | 100 | 33.01 |
| 11:40 ET | 200 | 33 |
| 11:42 ET | 800 | 33.056 |
| 11:44 ET | 400 | 33.14 |
| 11:47 ET | 200 | 33.08 |
| 11:49 ET | 100 | 33.105 |
| 11:51 ET | 200 | 33.07 |
| 11:54 ET | 300 | 33.04 |
| 11:56 ET | 1000 | 33.02 |
| 12:00 ET | 100 | 33.04 |
| 12:03 ET | 1166 | 32.89 |
| 12:09 ET | 400 | 32.97 |
| 12:18 ET | 742 | 33.01 |
| 12:20 ET | 100 | 33.01 |
| 12:21 ET | 200 | 33.05 |
| 12:23 ET | 300 | 33 |
| 12:25 ET | 600 | 33.05 |
| 12:27 ET | 500 | 33.1 |
| 12:30 ET | 500 | 33.15 |
| 12:34 ET | 200 | 33.15 |
| 12:36 ET | 100 | 33.17 |
| 12:39 ET | 500 | 33.25 |
| 12:41 ET | 200 | 33.295 |
| 12:43 ET | 500 | 33.22 |
| 12:45 ET | 100 | 33.22 |
| 12:48 ET | 590 | 33.3 |
| 12:50 ET | 100 | 33.265 |
| 12:52 ET | 100 | 33.315 |
| 12:54 ET | 1105 | 33.28 |
| 12:56 ET | 3525 | 33.265 |
| 12:59 ET | 1200 | 33.25 |
| 01:01 ET | 900 | 33.31 |
| 01:06 ET | 100 | 33.245 |
| 01:08 ET | 100 | 33.24 |
| 01:12 ET | 200 | 33.33 |
| 01:15 ET | 198 | 33.326 |
| 01:17 ET | 1088 | 33.31 |
| 01:24 ET | 200 | 33.36 |
| 01:26 ET | 300 | 33.27 |
| 01:30 ET | 300 | 33.38 |
| 01:32 ET | 100 | 33.37 |
| 01:33 ET | 100 | 33.37 |
| 01:35 ET | 700 | 33.4 |
| 01:37 ET | 200 | 33.39 |
| 01:39 ET | 300 | 33.34 |
| 01:42 ET | 258 | 33.37 |
| 01:44 ET | 400 | 33.27 |
| 01:46 ET | 300 | 33.315 |
| 01:50 ET | 600 | 33.35 |
| 01:51 ET | 200 | 33.335 |
| 01:53 ET | 300 | 33.358 |
| 01:57 ET | 200 | 33.36 |
| 02:02 ET | 100 | 33.37 |
| 02:04 ET | 800 | 33.37 |
| 02:06 ET | 100 | 33.39 |
| 02:08 ET | 711 | 33.27 |
| 02:09 ET | 400 | 33.27 |
| 02:11 ET | 100 | 33.27 |
| 02:13 ET | 300 | 33.28 |
| 02:15 ET | 100 | 33.28 |
| 02:18 ET | 400 | 33.32 |
| 02:20 ET | 9185 | 33.2 |
| 02:22 ET | 200 | 33.23 |
| 02:26 ET | 100 | 33.28 |
| 02:31 ET | 300 | 33.36 |
| 02:33 ET | 700 | 33.27 |
| 02:36 ET | 100 | 33.32 |
| 02:40 ET | 1315 | 33.31 |
| 02:45 ET | 100 | 33.28 |
| 02:47 ET | 900 | 33.36 |
| 02:49 ET | 600 | 33.33 |
| 02:51 ET | 300 | 33.345 |
| 02:58 ET | 800 | 33.386 |
| 03:00 ET | 100 | 33.31 |
| 03:02 ET | 500 | 33.37 |
| 03:03 ET | 100 | 33.36 |
| 03:05 ET | 100 | 33.395 |
| 03:07 ET | 513 | 33.37 |
| 03:09 ET | 769 | 33.36 |
| 03:12 ET | 700 | 33.36 |
| 03:14 ET | 1300 | 33.38 |
| 03:16 ET | 400 | 33.37 |
| 03:18 ET | 2600 | 33.38 |
| 03:20 ET | 2089 | 33.31 |
| 03:21 ET | 2218 | 33.215 |
| 03:23 ET | 1100 | 33.185 |
| 03:25 ET | 400 | 33.14 |
| 03:27 ET | 1438 | 33.225 |
| 03:30 ET | 300 | 33.254 |
| 03:32 ET | 300 | 33.25 |
| 03:34 ET | 400 | 33.31 |
| 03:36 ET | 1245 | 33.27 |
| 03:39 ET | 500 | 33.26 |
| 03:41 ET | 939 | 33.29 |
| 03:43 ET | 562 | 33.32 |
| 03:45 ET | 713 | 33.271 |
| 03:48 ET | 1123 | 33.24 |
| 03:50 ET | 612 | 33.28 |
| 03:52 ET | 1500 | 33.28 |
| 03:54 ET | 948 | 33.315 |
| 03:56 ET | 4079 | 33.35 |
| 03:57 ET | 3736 | 33.365 |
| 03:59 ET | 8494 | 33.38 |
May 23, 2023
Goldman Sachs Adjusts Price Target on Cerevel Therapeutics to $30 From $31, Keeps Neutral Rating, from 7:55AM ET on Tuesday May 23, 2023 by MT Newswires
7:55AM ET on Tuesday May 23, 2023 by MT Newswires
May 10, 2023
Cerevel Therapeutics Holdings Names Susan Altschuller CFO, from 8:03AM ET on Wednesday May 10, 2023 by MT Newswires
8:03AM ET on Wednesday May 10, 2023 by MT NewswiresBRIEF-Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. As CFO, from 7:37AM ET on Wednesday May 10, 2023 by Thomson Reuters
7:37AM ET on Wednesday May 10, 2023 by Thomson Reuters
May 8, 2023
Insider Sell: Cerevel Therapeutics Holdings, from 4:29PM ET on Monday May 08, 2023 by MT Newswires
4:29PM ET on Monday May 08, 2023 by MT Newswires--Mizuho Securities Adjusts Cerevel Therapeutics Price Target to $29 From $26, Maintains Neutral Rating, from 8:05AM ET on Monday May 08, 2023 by MT Newswires
8:05AM ET on Monday May 08, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cerevel Therapeutics Holdings Inc | 5.2B | -13.2x | --- |
IVERIC bio Inc | 5.2B | -21.6x | --- |
CRISPR Therapeutics AG | 5.1B | -9.7x | --- |
Madrigal Pharmaceuticals Inc | 4.8B | -14.4x | --- |
Vaxcyte Inc | 4.8B | -14.8x | --- |
Ascendis Pharma A/S | 5.2B | -8.4x | --- |
Company Information
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Its pipeline with various clinical trials underway or planned, including three ongoing Phase III trials and an open-label extension trial for tavapadon in Parkinson's, two planned Phase II trials and a planned open-label extension trial for emraclidine in schizophrenia and an ongoing Phase II proof-of-concept trial with an open-label extension trial for darigabat in focal epilepsy.
Contact Information
- Headquarters
- 222 Jacobs Street, Suite 200CAMBRIDGE, MA, United States 02141
- Phone
- 212-284-2300
- Fax
- 302-636-5454
Executives
- Chairperson of the Board of Directors
- N. Anthony Coles
- Chief Financial Officer
- Susan Altschuller
- Chief Human Resources Officer
- Kenneth Dipietro
- Senior Vice President - Finance, Chief Accounting Officer
- Mark Bodenrader
- Chief Scientific Officer
- John Renger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.2B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 156.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.53 |
Book Value | $3.33 |
P/E Ratio | -13.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
